Search results for "DMARDs"
showing 4 items of 4 documents
Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index
2020
We read with interest the recently published paper from McGonagle et al 1 analysing the role of interleukin (IL)-17A in axial spondyloarthritis and psoriatic arthritis (PsA). The meta-analysis and functional study provided by the authors highlighted the efficacy of IL-17A block by secukinumab in the treatment of PsA. However, there is no mention of the role of body mass index (BMI), if any, in influencing the clinical response to secukinumab, given the lack of published data. PsA is a chronic inflammatory arthritis burdened by a series of metabolic comorbidities. Among them, obesity is very common in PsA, with a prevalence of 27%, as confirmed by a recent Spanish work.2 Obesity in PsA has b…
Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…
2009
The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…
Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment
2020
Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.
A Systematic review to identify the effects of biologics in the feet of patients with rheumatoid arthritis
2020
Background and objective: Ninety percent of patients with rheumatoid arthritis (RA) feel foot pain during the disease process. Pharmacological treatment of RA has a systematic effect on the body and includes: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. The objective of our review was to examine the impact of biologics on patients with RA ‘foot. Methods and material: A systematic review of randomized control trials and observational studies that evaluated the efficacy of biologics against other pharmacological treatment, and included a foot outcome measure. The search covered MEDLINE Ovid, Pubmed, CINAHL, Cochrane Library, Evidence Sear…